Form 4: United Therapeutics Director Christopher Patusky Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Director Christopher Patusky exercised stock options and sold shares of United Therapeutics Corp (UTHR) on March 19, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On March 19, 2025, Christopher Patusky, a director of United Therapeutics Corporation, executed stock options and sold shares of the company's common stock.
- The transactions were carried out under a Rule 10b5-1 trading plan established on August 27, 2024.
- Patusky exercised options for 5,000 shares at a price of $175.43 per share.
- He then sold a total of 5,000 shares in multiple transactions at weighted average prices ranging from $307.7332 to $313.77.
- Following these transactions, Patusky directly owns 1,000 shares and indirectly owns 1,100 shares through a trust.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-arranged trading plan. There is no indication of positive or negative sentiment towards the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It is common for executives and directors to utilize Rule 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information. The filing itself doesn't necessarily indicate a positive or negative outlook for the company.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership by a director.
- The impact is likely minimal as the transactions were executed under a pre-arranged trading plan.
Key Dates
| Date | Description |
|---|---|
| 06/26/2016 | Original date of the stock options that were exercised. |
| 08/27/2024 | Date the Rule 10b5-1 trading plan was entered into. |
| 03/19/2025 | Date of the stock option exercise and share sales. |
| 03/20/2025 | Date of signature on the Form 4 filing. |
| 06/26/2025 | Expiration date of the stock options that were exercised. |
Keywords
United Therapeutics, UTHR, Christopher Patusky, stock options, Rule 10b5-1, insider trading, Form 4, share sale, director, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.